Bayer Renews Deal to Make MRI Contrast Media
November 13, 2007 - Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, has been awarded a three-year contract renewal by HealthTrust Purchasing Group, LP (HealthTrust), to make Magnevist (gadopentetate dimeglumine) Injection, a magnetic resonance imaging (MRI) contrast agent, for members of the HealthTrust network.
For the past seven years, Berlex, Inc. has provided the HealthTrust membership with MRI contrast media. Berlex is now part of Bayer HealthCare Pharmaceuticals as a result of Bayer’s acquisition of Berlex's affiliate, Schering AG Germany. The new agreement calls for Bayer HealthCare Pharmaceuticals to continue as a provider of MRI contrast media to HealthTrust for the next three years.
The agreement, which was effective September 1, 2007, extends through August 31, 2010, and includes 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and 20 mL pre-filled syringes of Magnevist.
For more information: www.imaging.bayerhealthcare.com